Crewe Advisors’s Seres Therapeutics MCRB Stock Holding History

Crewe Advisors’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-34	Closed	-$3.83K	–	964
2023 Q1	$3.83K	Hold	34	–	–	﹤0.01%	663
2022 Q4	$3.79K	Hold	34	–	–	﹤0.01%	731
2022 Q3	$4K	Hold	34	–	–	﹤0.01%	901
2022 Q2	$2K	Buy	+34	New	+$2.93K	﹤0.01%	986

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Crewe Advisors's MCRB Position: Q2 2023 in Review

Crewe Advisors sold out of Seres Therapeutics (MCRB) in Q2 2023, closing a stake of 34 shares — an estimated $3.83K sold.

Crewe Advisors first reported a position in MCRB in Q2 2022 and held it in 4 quarters. The position peaked at $4K in Q3 2022. 137 funds tracked by Wall St. Rank hold MCRB as of Q2 2023.

Crewe Advisors reported no remaining Seres Therapeutics position as of Q2 2023 after selling out during the quarter.
Crewe Advisors sold 34 Seres Therapeutics shares in Q2 2023, an estimated $3.83K.
Crewe Advisors first reported a position in Seres Therapeutics in Q2 2022 and held it in 4 quarters.
Crewe Advisors's Seres Therapeutics position peaked at $4K in Q3 2022.
137 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2023.

Based on Crewe Advisors's 13F filing for Q2 2023, filed 28 Jul 2023.